Citius Pharmaceuticals (CTXR) investor relations material

Company background and structure

• Founded in 2014, with significant direct investment from founders and a public listing achieved via SPAC acquisition.

• Structure includes a parent (Citius Pharmaceuticals) and subsidiary (Citius Oncology), with shared management to minimize expenses.

• Key assets include LYMPHIR (oncology), Mino-Lok (infected catheter treatment), and Halo-Lido (hemorrhoid drug).

LYMPHIR launch and commercialization

• LYMPHIR approved for cutaneous T-cell lymphoma (CTCL), targeting a $400–$500 million market, with U.S. rights secured.

• Early sales achieved with a small team; full sales force of 29 deployed recently, expected to impact results in late 2026 and early 2027.

• $7.1 million in revenue generated in less than nine months, with 44 institutions and 135 health plans adopting the drug.

• Gross margin stands at 77%, aided by lack of managed care rebates due to hospital drug status.

• Inventory is robust, with a five-year shelf life, and payer access is comprehensive.

Clinical and market insights

• LYMPHIR’s mechanism targets IL-2 receptors, depleting Tregs and showing a 36% objective response rate in trials.

• Durable responses and manageable side effects reported; competition includes ADCETRIS and Poteligeo.

• Market is concentrated geographically and among a small number of providers, facilitating targeted sales.